Related references
Note: Only part of the references are listed.Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Enliang Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis
Lan Zhang et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2021)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan et al.
SCIENCE (2020)
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Jiyong Liang et al.
CANCER IMMUNOLOGY RESEARCH (2020)
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
Jinghui Liu et al.
ONCOGENE (2020)
A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer
Qianwen Zhang et al.
CLINICAL CANCER RESEARCH (2019)
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Rui-Yan Wu et al.
CLINICAL CANCER RESEARCH (2019)
PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
Xinyi Tu et al.
MOLECULAR CELL (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma
Neeraj Jain et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
Lulu Shao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Ludovic Fournel et al.
CANCER LETTERS (2019)
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Wendy Mao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The bromodomain protein BRD4 positively regulates necroptosis via modulating MLKL expression
Yu Xiong et al.
CELL DEATH AND DIFFERENTIATION (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
Shannon Grabosch et al.
ONCOGENE (2019)
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
Aurelie Hanoteau et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
Liliang Xia et al.
ONCOLOGIST (2019)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model
Yan Liu et al.
CANCER RESEARCH (2018)
PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
Shisuo Du et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
Frank P. Vendetti et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer
Dennis O. Adeegbe et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
Teppei Yamaguchi et al.
LUNG CANCER (2018)
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma
Michael Cerezo et al.
NATURE MEDICINE (2018)
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer
Xiaomei Gong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Takao Fujisawa et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer
Dennis O. Adeegbe et al.
CANCER DISCOVERY (2017)
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
Simon J. Hogg et al.
CELL REPORTS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies
Alexander K. Tsai et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Linda Tran et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Ombretta Melaiu et al.
CLINICAL CANCER RESEARCH (2017)
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Heath D. Skinner et al.
CLINICAL CANCER RESEARCH (2017)
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis
Markus Hecht et al.
EUROPEAN JOURNAL OF CANCER (2016)
Predictive relevance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Takaaki Tokito et al.
EUROPEAN JOURNAL OF CANCER (2016)
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
Yuki Kagoya et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
Maria Pia Abruzzese et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Hengrui Zhu et al.
CELL REPORTS (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Takeshi Shimamura et al.
CLINICAL CANCER RESEARCH (2013)
Osteopontin Does Not Mitigate Cisplatin Ototoxicity or Nephrotoxicity in Adult Mice
Nicole C. Schmitt et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2013)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
William W. Lockwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
Anne Auperin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Definitive chemoradiation for the treatment of locally advanced non-small-cell lung cancer
A. William Blackstock et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Share Paper
